Business Standard

Dr Reddy's Labs announces generic version of Straterra in US market

The Strattera brand had US sales of around $304 million for the most recent 12 months ending in August 2018

Pharmaceuticals, drugs, pharma industry, medical, health, lab

Press Trust of India New Delhi
Dr Reddy's Laboratories Wednesday announced the launch of Atomoxetine capsules used to treat attention-deficit hyperactivity disorder (ADHD) in the US market.
The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Eli Lilly and Company's Straterra, Dr Reddy's Laboratories said in a statement.
As per the IMS Health sales data, the Strattera brand had US sales of around $304 million for the most recent 12 months ending in August 2018.
Shares of Dr Reddy's Laboratories were trading 1.87 per cent down at Rs 2,549 on the BSE.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 31 2018 | 1:50 PM IST

Explore News